Alembic announces USFDA tentative approval for Selexipag for Injection, 1,800 mcg/vial
Selexipag is a prostacyclin receptor agonist indicated for the treatment of pulmonary arterial hypertension
Selexipag is a prostacyclin receptor agonist indicated for the treatment of pulmonary arterial hypertension
Dyslipidemia is a critical risk factor for cardiovascular diseases
Azilsartan Medoxomil and Chlorthalidone Tablets had annual sales of US$ 77.9 mn in the United States (IQVIA MAT March 24).
35,000 doctors from across India pledged their support for the initiative to raise awareness about cardiovascular diseases
These devices instantly detect various arrhythmias, including atrial fibrillation (Afib), bradycardia, tachycardia, and more
Receives 3 final and 2 tentative product approvals thus far in Q1FY25
Travoprost Ophthalmic Solution USP, 0.004%, is indicated for the reduction of elevated intraocular pressure in patients with open angle glaucoma or ocular hypertension.
Sales reflect continued strong growth in oncology and vaccines
The Institute is catering the health needs of the surrounding population with ever-increasing OPD every year along with special OPDs like mother & Child OPD, and LSD clinic
Subscribe To Our Newsletter & Stay Updated